Lenvatinib plus pembrolizumab versus lenvatinib in patients with unresectable hepatocellular carcinoma: A real world study.

I-Cheng Lee,Chi-Jung Wu,San-Chi Chen,Yee Chao,Yi-Hsiang Huang

Lenvatinib plus pembrolizumab versus lenvatinib in patients with unresectable hepatocellular carcinoma: A real world study.

2021

I-Cheng Lee
Chi-Jung Wu
San-Chi Chen
Yee Chao
Yi-Hsiang Huang

e16138Background: The combination of lenvatinib (LEN) and pembrolizumab (PEMBRO) showed promising response rates and survival in a phase 1b trial for patients with unresectable hepatocellular carci...

Keywords:

in patient
Oncology
Medicine
Lenvatinib
Internal medicine
Hepatocellular carcinoma
Pembrolizumab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations